Aromics Therapeutics
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors (NCT06652529) | Aromics Therapeutics | 2025-01-01 |
Track Aromics Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.